Larimar Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Deerfield Management Company and its affiliated funds increased their beneficial ownership in Larimar Therapeutics, Inc. to 34.41% through a $25 million share purchase in a recent offering.
NASDAQ
SCHEDULE: Deerfield Funds Boost Stake in Larimar Therapeutics to 35.81% Following $30 Million Offering
Deerfield Management and its affiliated funds have increased their beneficial ownership in Larimar Therapeutics, Inc. to 35.81% of common stock after acquiring an additional 9.37 million shares for $30 million in a recent underwritten offering.